As a clinician, corporate leader, and biotech entrepreneur with over 25 years in global executive roles within medical device and regenerative medicine organisations, my mission has always been clear: to restore patients’ quality of life, improve patient outcomes, and reduce the strain on healthcare systems. The opportunity to drive meaningful change in wound care has never been greater.

Despite advancements in areas such as negative pressure wound therapy, overall chronic wound healing rates have remained stubbornly low for decades, even the FDA has called for a new approach. Looking back, have we, the industry, fallen into a mindset of merely ‘managing’ wounds rather than actively healing them?  

Debridement in particular remains inadequately addressed. Many debridement approaches are notoriously slow and ineffective, while those that are quicker are typically viable only for ‘one-off’, or periodic use and bear much higher risk to the patients. These methods address the immediate symptom during a given treatment session but fall short of guiding the wound through its full healing journey. In many cases, wounds that are initially debrided become sloughy or infected again, disrupting the healing trajectory. While debridement should mark the start of healing, it must also be continuous - a sustained therapeutic component until the wound is healed and no longer at risk of regression.

Despite these challenges I am increasingly optimistic that the industry is at a turning point, shifting from passive wound care to active wound therapy and wound healing, treating the root causes of chronic wounds and setting them on a true healing trajectory. Some emerging technologies will enhance the healing process; others will redefine it entirely. Encouragingly, even large, device-driven wound care companies are now investing in bold, progressive solutions, as seen in Convatec’s £176 million acquisition and subsequent launch of 30 Technology’s nitric oxide platform and Coloplast’s $1.3 billion acquisition of Kerecis. Yet, the unmet need remains vast.

This is why I joined SolasCure as Chairman of the Board, not because the path is easy, but because the need is urgent. With decades of experience at the intersection of clinical practice and healthcare innovation, I’ve seen firsthand how truly patient-centered solutions must be both clinically viable and practically accessible.

Our mission to develop a powerful, easy-to-use enzymatic therapy for debridement and healing, backed by strong clinical evidence, has the potential to revolutionise chronic wound treatment and shift the paradigm from merely managing wounds to actively promoting healing and patient well-being. We must move beyond incremental improvements and commit to truly transformative therapies. My role is to help guide that vision, ensuring our innovations are not only scientifically meaningful, but positioned to make a real-world difference across global healthcare systems. The time for change is now.

Author: Andy Weymann, MD, Chairman of the Board

A surgeon by background and formerly Chief Medical Officer at Smith & Nephew, Andy brings not only deep sector experience, but also more than 25 years of executive and board experience in global medical device, biopharma & regenerative medicine companies to SolasCure.